Organogenesis Holdings Inc (NASDAQ:ORGO) has a beta value of 1.79 and has seen 3.69 million shares traded in the last trading session. The company, currently valued at $549.17M, closed the last trade at $4.33 per share which meant it gained $0.12 on the day or 2.85% during that session. The ORGO stock price is -54.97% off its 52-week high price of $6.71 and 50.12% above the 52-week low of $2.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.57 million shares traded. The 3-month trading volume is 1.95 million shares.
The consensus among analysts is that Organogenesis Holdings Inc (ORGO) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
Organogenesis Holdings Inc (NASDAQ:ORGO) trade information
Over the past 30 days, the shares of Organogenesis Holdings Inc (NASDAQ:ORGO) have changed -11.27%. Short interest in the company has seen 9.99 million shares shorted with days to cover at 2.4.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 27.83% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -38.57% off the targeted high while a plunge would see the stock gain -38.57% from current levels.
Organogenesis Holdings Inc (ORGO) estimates and forecasts
The company’s shares have gained 41.04% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 1.29%.
3 analysts offering their estimates for the company have set an average revenue estimate of 90.77M for the current quarter. 3 have an estimated revenue figure of 102.17M for the next ending quarter. Year-ago sales stood 109.98M and 130.23M respectively for this quarter and the next, and analysts expect sales will shrink by -17.47% for the current quarter and 1.29% for the next.
ORGO Dividends
Organogenesis Holdings Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Organogenesis Holdings Inc (NASDAQ:ORGO)’s Major holders
Insiders own 46.66% of the company shares, while shares held by institutions stand at 48.12% with a share float percentage of 90.20%. Investors are also buoyed by the number of investors in a company, with Organogenesis Holdings Inc having a total of 160.0 institutions that hold shares in the company. The top two institutional holders are MORGAN STANLEY with over 11.58 million shares worth more than $32.41 million. As of 2024-06-30, MORGAN STANLEY held 8.7318% of shares outstanding.
The other major institutional holder is SOLEUS CAPITAL MANAGEMENT, L.P., with the holding of over 11.52 million shares as of 2024-06-30. The firm’s total holdings are worth over $32.25 million and represent 8.6888% of shares outstanding.
